Navigation Links
Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

vice to regulate heart function.

ABOUT BIOHEART, INC.

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell, is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell SDF-1, a therapy utilizing autologous cells genetically modified to express additional growth factors.

FOOTNOTES

(1) SEISMIC: Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell(R)) using an Injection Catheter

(2) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post-Myocardial Infarction(s)

(3) The MYOSTAR(TM) Injection Catheter is not available for sale in the U.S. It is in use in IND investigations

(4) Heart Association Heart Disease Statistics - 2007 Update

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company

For more information, visit http://www.bioheartinc.com


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
5. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
6. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... million to Allina Hospitals & Clinics to study the ... for patients at Abbott Northwestern Hospital in Minneapolis, Minn. ... Healing and the Center for Healthcare Innovation at Allina ... "Integrative medicine emphasizes a full range of personalized healthy ...
... The position of the foot just before ground contact during ... sprains, according to a new study published by a University ... which appear in the June online edition of the ... have a history of repetitive ankle sprains demonstrated lower clearance ...
... African-Americans are less likely than whites to receive ... to a hospital soon enough for time-sensitive treatment and ... are eligible for treatment, no racial disparity was found. ... University Medical Center study involving the review of almost ...
... Today the International and American Associations for Dental Research announced ... ) has increased its Five-Year Scientific Impact Factor (SIF) from ... category, the Journal ranked #1 in Article Influence. This news ... rankings, published by the Journal Citation Reports (JCR). This latest ...
... on eligibility for health care reform programs will result in ... health care coverage in California, according to a new policy ... The number represents approximately 20 percent of all ... up to 40,000 may be eligible for coverage but may ...
... Chase Cancer Center have discovered a new mechanism used by ... process is critical in preventing the development of cancersuggesting the ... underlying the disease. The findings will be published online ... The process investigated by Alfonso Bellacosa, M.D., Ph.D., Associate ...
Cached Medicine News:Health News:Allina receives NIH grant to study real world usage of integrative therapies 2Health News:Foot positioning during walking and running may influence ankle sprains 2Health News:Georgetown research identifies key reasons racial disparities exist in emergent stroke treatment 2Health News:Journal of Dental Research increases its scientific impact factor 2Health News:Up to 220,000 California children excluded from health care reform due to immigrant status 2Health News:Fox Chase researchers identify new mechanism used by cells to reverse silenced genes 2
... / DVD Burner captures still images ... 50 patient archives allows for multiple ... retrieval. The unit provides software burned ... easy playback and editing. Compatible with ...
LCD monitors....
Camera and light source in one compact "Plug-and-Play" device....
... a highly sensitive DR system. It features ... it is designed for most general radiographic ... multiple wall stand and table configurations. , ... efficiently produces detailed patient images with reduced ...
Medicine Products: